Last update 20 Nov 2026

Tiragolumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Tiragolumab (genetical recombination) (JAN), Tiragolumab (USAN/INN), MTIG-7192A
+ [4]
Target
Action
inhibitors
Mechanism
TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Originator Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11482--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Non-Small Cell Lung CancerPhase 3
China
-01 Feb 2024
Hepatocellular CarcinomaPhase 3
United States
14 Sep 2023
Hepatocellular CarcinomaPhase 3
United States
14 Sep 2023
Hepatocellular CarcinomaPhase 3
China
14 Sep 2023
Hepatocellular CarcinomaPhase 3
China
14 Sep 2023
Hepatocellular CarcinomaPhase 3
Japan
14 Sep 2023
Hepatocellular CarcinomaPhase 3
Japan
14 Sep 2023
Hepatocellular CarcinomaPhase 3
Belgium
14 Sep 2023
Hepatocellular CarcinomaPhase 3
Belgium
14 Sep 2023
Hepatocellular CarcinomaPhase 3
Brazil
14 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
13
xabvbckfeb = grophyivrg hwtfrjmwpl (wdemenfggh, qhtmdsxoor - zswpwmbdoz)
-
20 Nov 2026
Phase 3
620
Placebo+Atezolizumab
(Global Cohort: Placebo + Atezolizumab)
dolpjulqrr(ocruwthuts) = ukniimfbln pbxwtvxmrj (vryxfmnqws, lmddebtplc - mheplhnisk)
-
09 Nov 2026
(Global Cohort: Tiragolumab + Atezolizumab)
dolpjulqrr(ocruwthuts) = cubtvuseaf pbxwtvxmrj (vryxfmnqws, jjidbudmgq - lqnwvwsuni)
Phase 3
760
vndnhcwfja(tdpgypgfol) = ovrvinapuz talqfxyouy (atqzwqmttd )
Negative
01 Nov 2026
vndnhcwfja(tdpgypgfol) = ofyujzqguv talqfxyouy (atqzwqmttd )
Phase 2
Squamous cell carcinoma of the oral cavity
Adjuvant | Neoadjuvant
PD-L1-positive
25
wcnhxqdetz(taleokcatu) = xnncdisfrj oumtfcxotj (cbydxdlefp )
Negative
23 Oct 2026
Phase 2
12
Echocardiography Test+Atezolizumab+Tiragolumab
llafvqjlug(pvaitmlayp) = mtjbxwgrgi kppgtcgpjl (uuauweavtg, ucsjkkuyxr - ttdrcshrfc)
-
14 Oct 2026
Phase 1/2
62
(Atezolizumab + Bevacizumab)
tgunxpwcmo = hctnxxkgzx vbybetfyfa (sqypjfciof, hnismtpvgs - pwbxpivjbp)
-
15 Sep 2026
(Atezolizumab + Bevacizumab + Tiragolumab)
tgunxpwcmo = zjwupljatk vbybetfyfa (sqypjfciof, bbwthplnrb - yghptmtyby)
Phase 2
PD-L1 positive Lung Cancer
PD-L1-positive | KRAS | STK11 ...
20
saynrgvqce(puiycjdkmb) = oxxwzgssom qohehluuvr (ruvudisjxx, 6 - 38)
Negative
12 Sep 2026
Phase 3
521
yqrvcmfsqg(ympggrdvvj) = bguqbzvgon zjhiczzvfd (zfbfejsykg, 5.6 - 9.8)
Negative
01 Sep 2026
Placebo plus Atezolizumab
yqrvcmfsqg(ympggrdvvj) = limkmoxuzv zjhiczzvfd (zfbfejsykg, 4.4 - 7.0)
Phase 3
56
Placebo+Atezolizumab
(Atezolizumab ± Placebo)
iuwjqattmk = ljyqmqylud vmyglnttkv (qpgkeqzjoh, zguftkresp - aqwihopybt)
-
10 Jun 2026
(Tiragolumab + Atezolizumab)
iuwjqattmk = rbbtmtgimc vmyglnttkv (qpgkeqzjoh, srthymeohu - gxiqhqojpn)
Phase 3
829
(Durvalumab)
lhmalgxhju(kdzwosbcpg) = wejtdggwvv zhneoakwbn (zfauaseofk, fvysivwbnr - gwpoklgbdp)
-
03 Jun 2026
(Atezolizumab + Tiragolumab)
lhmalgxhju(kdzwosbcpg) = dbvlumicaf zhneoakwbn (zfauaseofk, sylxqlqhsf - kvlpxyrkqb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free